|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katanoda K, Hori M, Matsuda T, Shibata A,
Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An
updated report on the trends in cancer incidence and mortality in
Japan, 1958–2013. Jpn J Clin Oncol. 45:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matsuda T, Ajiki W, Marugame T, Ioka A,
Tsukuma H and Sobue T: Research group of population-based cancer
registries of Japan: Population-based survival of cancer patients
diagnosed between 1993 and 1999 in Japan: A chronological and
international comparative study. Jpn J Clin Oncol. 41:40–51. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mawby WJ, Holmes CH, Anstee DJ, Spring FA
and Tanner MJ: Isolation and characterization of CD47 glycoprotein:
A multispanning membrane protein which is the same as
integrin-associated protein (IAP) and the ovarian tumour marker
OA3. Biochem J. 304:525–530. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reinhold MI, Lindberg FP, Plas D, Reynolds
S, Peters MG and Brown EJ: In vivo expression of alternatively
spliced forms of integrin-associated protein (CD47). J cell Sci.
108:3419–3425. 1995.PubMed/NCBI
|
|
6
|
Oldenborg PA, Zheleznyak A, Fang YF,
Lagenaur CF, Gresham HD and Lindberg FP: Role of CD47 as a marker
of self on red blood cells. Science. 288:2051–2054. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jaiswal S, Jamieson CH, Pang WW, Park CY,
Chao MP, Majeti R, Traver D, van Rooijen N and Weissman IL: CD47 is
upregulated on circulating hematopoietic stem cells and leukemia
cells to avoid phagocytosis. Cell. 138:271–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chao MP, Weissman IL and Majeti R: The
CD47-SIRPα pathway in cancer immune evasion and potential
therapeutic implications. Curr Opin Immunol. 24:225–232. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan KS, Espinosa I, Chao M, Wong D,
Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, et
al: Identification, molecular characterization, clinical prognosis,
and therapeutic targeting of human bladder tumor-initiating cells.
Proc Natl Acad Sci USA. 106:pp. 14016–14021. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagahara M, Mimori K, Kataoka A, Ishii H,
Tanaka F, Nakagawa T, Sato T, Ono S, Sugihara K and Mori M:
Correlated expression of CD47 and SIRPA in bone marrow and in
peripheral blood predicts recurrence in breast cancer patients.
Clin Cancer Res. 16:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Pu Y, Cron K, Deng L, Kline J,
Frazier WA, Xu H, Peng H, Fu YX and Xu MM: CD47 blockade triggers T
cell-mediated destruction of immunogenic tumors. Nat Med.
21:1209–1215. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soto-Pantoja DR, Stein EV, Rogers NM,
Sharifi-Sanjani M, Isenberg JS and Roberts DD: Therapeutic
opportunities for targeting the ubiquitous cell surface receptor
CD47. Expert Opin Ther Targets. 17:89–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
Cancer. 20:1–19. 2017. View Article : Google Scholar
|
|
14
|
Chomczynski P: A reagent for the
single-step simultaneous isolation of RNA, DNA and proteins from
cell and tissue samples. Bio Techniques. 15:532–534, 536-537.
1993.
|
|
15
|
Inoue H, Mori M, Honda M, Li J, Shibuta K,
Mimori K, Ueo H and Akiyoshi T: The expression of tumor-rejection
antigen ‘MAGE’ genes in human gastric carcinoma. Gastroenterology.
109:1522–1525. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Majeti R, Chao MP, Alizadeh AA, Pang WW,
Jaiswal S, Gibbs KD Jr, van Rooijen N and Weissman IL: CD47 is an
adverse prognostic factor and therapeutic antibody target on human
acute myeloid leukemia stem cells. Cell. 138:286–299. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chao MP, Alizadeh AA, Tang C, Jan M,
Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL and Majeti R:
Therapeutic antibody targeting of CD47 eliminates human acute
lymphoblastic leukemia. Cancer Res. 71:1374–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoffmann W: Regeneration of the gastric
mucosa and its glands from stem cells. Curr Med Chem. 15:3133–3144.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoffmann W: Stem cells, self-renewal and
cancer of the gastric epithelium. Curr Med Chem. 19:5975–5983.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee ER and Leblond CP: Dynamic histology
of the antral epithelium in the mouse stomach: II. Ultrastructure
and renewal of isthmal cells. Am J Anat. 172:205–224. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimada H, Takiguchi N, Kainuma O, Soda H,
Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H and Nagata M: High
preoperative neutrophil-lymphocyte ratio predicts poor survival in
patients with gastric cancer. Gastric Cancer. 13:170–176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balta S, Unlu M, Arslan Z and Demırkol S:
Neutrophil-to- lymphocyte ratio in prognosis of gastric cancer. J
Gastric Cancer. 13:196–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho IR, Park JC, Park CH, Jo JH, Lee HJ,
Kim S, Shim CN, Lee H, Shin SK, Lee SK and Lee YC: Pre-treatment
neutrophil to lymphocyte ratio as a prognostic marker to predict
chemotherapeutic response and survival outcomes in metastatic
advanced gastric cancer. Gastric Cancer. 17:703–710. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Petrillo A, Laterza MM, Ventriglia J,
Savastano B, Tirino G, Pompella L, Martinelli E, Morgillo F,
Orditura M, Ciardiello F and De Vita F: Prognostic implications of
baseline neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte
ratio (PLR) in metastatic gastric cancer (GC) patients. Ann Oncol.
27:(Suppl 6): 652P2016. View Article : Google Scholar
|
|
26
|
Zhang X, Zhang W and Feng LJ: Prognostic
significance of neutrophil lymphocyte ratio in patients with
gastric cancer: A meta-analysis. PLoS One. 9:e1119062014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim
KH and Kim HJ: Prognostic significance of neutrophil lymphocyte
ratio and platelet lymphocyte ratio in advanced gastric cancer
patients treated with FOLFOX chemotherapy. BMC Cancer. 13:3502013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirashima M, Higuchi S, Sakamoto K,
Nishiyama T and Okada H: The ratio of neutrophils to lymphocytes
and the phenotypes of neutrophils in patients with early gastric
cancer. J Cancer Res Clin Oncol. 124:329–334. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamanaka T, Matsumoto S, Teramukai S,
Ishiwata R, Nagai Y and Fukushima M: The baseline ratio of
neutrophils to lymphocytes is associated with patient prognosis in
advanced gastric cancer. Oncology. 73:215–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito H, Takaya S, Osaki T and Ikeguchi M:
Increased apoptosis and elevated Fas expression in circulating
natural killer cells in gastric cancer patients. Gastric Cancer.
16:473–479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshida K, Tsujimoto H, Matsumura K,
Kinoshita M, Takahata R, Matsumoto Y, Hiraki S, Ono S, Seki S,
Yamamoto J and Hase K: CD47 is an adverse prognostic factor and a
therapeutic target in gastric cancer. Cancer Med. 4:1322–1333.
2015. View
Article : Google Scholar : PubMed/NCBI
|
